Kiora Pharmaceuticals, Inc.
corporate_fare Company Profile
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for KPRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for KPRX spans 10-Q, 8-K, 424B3, S-3.
Recent high-impact activity:
- Kiora Q3 10-Q: Going-Concern Warning, $6.2M Nine-Month Loss, KIO-104 Shelved
- Kiora In-Licenses Phase 3-Ready CRAO Drug KIO-401 for $3.5M Upfront, Up to $168.5M Milestones
- Kiora Licenses KIO-301 South Korea Rights to CKD for $1M Upfront
- Kiora Q2 2026: $16.8M Cash, Runway into Late 2028, and Clinical Momentum
- Kiora Reports Positive Preclinical Data for KIO-300 in Epilepsy Model, Expanding Platform Potential
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 56,588 shares in KPRX as of the October 30, 2026 settlement, a 1248.6% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 19, 2026, 17.9% of KPRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for KPRX, detected from its recent SEC filings · based on capital-structure filings through 2026-05-28.
Massive Potential Dilution · No Direct Company Proceeds from Resale
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →